Fennec Pharmaceuticals Analyst Ratings
Fennec Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 112.23% | HC Wainwright & Co. | $18 → $17 | Maintains | Buy |
| 06/21/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 04/06/2023 | 99.75% | Cantor Fitzgerald | $12 → $16 | Maintains | Overweight |
| 04/04/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 03/31/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/26/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 11/22/2022 | 49.81% | Cantor Fitzgerald | $9 → $12 | Upgrades | Neutral → Overweight |
| 10/20/2022 | 124.72% | HC Wainwright & Co. | $14 → $18 | Maintains | Buy |
| 09/26/2022 | 137.2% | Wedbush | $11 → $19 | Maintains | Outperform |
| 09/07/2022 | 37.33% | Capital One | → $11 | Initiates Coverage On | → Overweight |
| 08/08/2022 | 74.78% | Craig-Hallum | → $14 | Assumes | → Buy |
| 06/03/2021 | 74.78% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 04/21/2021 | 112.23% | Craig-Hallum | → $17 | Initiates Coverage On | → Buy |
| 04/19/2021 | 49.81% | Maxim Group | → $12 | Initiates Coverage On | → Buy |
| 06/05/2020 | 124.72% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 05/15/2020 | 87.27% | HC Wainwright & Co. | $17 → $15 | Reiterates | → Buy |
| 09/17/2018 | 99.75% | Wedbush | $17 → $16 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/04/2023 | 112.23% | HC Wainwright公司 | $18→$17 | 維護 | 買 |
| 2023年6月21日 | 124.72% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 04/06/2023 | 99.75% | 康託·菲茨傑拉德 | $12→$16 | 維護 | 超重 |
| 04/04/2023 | 124.72% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 03/31/2023 | 124.72% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 2023年1月26日 | 124.72% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 2022年11月22日 | 49.81% | 康託·菲茨傑拉德 | $9→$12 | 升級 | 中性→超重 |
| 10/20/2022 | 124.72% | HC Wainwright公司 | $14→$18 | 維護 | 買 |
| 09/26/2022 | 137.2% | 韋德布什 | $11→$19 | 維護 | 跑贏大盤 |
| 09/07/2022 | 37.33% | 大寫一 | →$11 | 開始承保 | →超重 |
| 2022/08/08 | 74.78% | 克雷格-哈勒姆 | →$14 | 假設 | →購買 |
| 06/03/2021 | 74.78% | HC Wainwright公司 | $15→$14 | 維護 | 買 |
| 04/21/2021 | 112.23% | 克雷格-哈勒姆 | →$17 | 開始承保 | →購買 |
| 04/19/2021 | 49.81% | Maxim集團 | →$12 | 開始承保 | →購買 |
| 06/05/2020 | 124.72% | 康託·菲茨傑拉德 | →$18 | 開始承保 | →超重 |
| 2020/05/15 | 87.27% | HC Wainwright公司 | $17→$15 | 重申 | →購買 |
| 2018年09月17日 | 99.75% | 韋德布什 | $17→$16 | 維護 | 跑贏大盤 |
What is the target price for Fennec Pharmaceuticals (FENC)?
Fennec PharmPharmticals(FENC)的目標價是多少？
The latest price target for Fennec Pharmaceuticals (NASDAQ: FENC) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $17.00 expecting FENC to rise to within 12 months (a possible 112.23% upside). 11 analyst firms have reported ratings in the last year.
芬內剋制藥公司(納斯達克代碼：FENC)的最新目標價是由HC Wainwright&Co.於2023年8月4日報道的。這家分析公司將目標價定為17美元，預計FENC將在12個月內上漲至(可能上漲112.23%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Fennec Pharmaceuticals (FENC)?
分析師對Fennec製藥公司(FENC)的最新評級是多少？
The latest analyst rating for Fennec Pharmaceuticals (NASDAQ: FENC) was provided by HC Wainwright & Co., and Fennec Pharmaceuticals maintained their buy rating.
分析師對芬內剋制藥公司(納斯達克代碼：FENC)的最新評級由HC Wainwright&Co.提供，芬內剋制藥公司維持買入評級。
When is the next analyst rating going to be posted or updated for Fennec Pharmaceuticals (FENC)?
Fennec PharmPharmticals(FENC)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fennec Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fennec Pharmaceuticals was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Fennec製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Fennec製藥的上一次評級是在2023年8月4日提交的，所以你應該預計下一次評級將在2024年8月4日左右的某個時候公佈。
Is the Analyst Rating Fennec Pharmaceuticals (FENC) correct?
分析師對Fennec製藥公司(FENC)的評級正確嗎？
While ratings are subjective and will change, the latest Fennec Pharmaceuticals (FENC) rating was a maintained with a price target of $18.00 to $17.00. The current price Fennec Pharmaceuticals (FENC) is trading at is $8.01, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Fennec製藥(FENC)評級維持不變，目標價在18.00美元至17.00美元之間。Fennec PharmPharmticals(FENC)目前的股價為8.01美元，超出了分析師的預測區間。